By Michael Gwarisa For decades, scientists have battled the elusive human immunodeficiency virus (HIV), whose ability to mutate and develop resistance has defeated one vaccine candidate after another. Now, a groundbreaking clinical trial under way in Zimbabwe and South Africa aims to outsmart the virus by targeting its most vulnerable, unchanging parts. The investigational vaccine, known scientifically as the Gorilla Adenovirus Vectored HIV Networked Epitopes Vaccine (GRAdHIVNE1), is designed to hit HIV where it hurts most: regions critical to its structure and function, making it harder for the virus to…
Read MoreNew HIV Vaccine trial targets mutation and Resistance
